The research team, led by Anne H. Zachry of the Department of Occupational Therapy at the University of Tennessee Health Sciences, together with colleagues spanning pediatrics, obstetrics, and preventive medicine, followed 58 infants from early infancy through their first birthday. Caregivers reported when they first introduced tummy time, choosing from prespecified categories ranging from the first two postnatal weeks to two months or older, or never. The infants were then divided into three groups: those introduced to tummy time within the first two postnatal weeks (22 infants), those introduced after the first two weeks (21 infants), and those whose caregivers reported never intentionally introducing it (15 infants). Development was assessed at 3, 6, 9, and 12 months using the Ages and Stages Questionnaire, Third Edition, a standardized parent-completed screening tool that measures communication, gross motor, fine motor, problem-solving, and personal-social skills.

The rationale for probing timing is grounded in developmental science. Prone positioning gives infants early opportunities to practice antigravity head and trunk control, upper-extremity weight bearing, postural adjustments, and active exploration of their environment. The early postnatal period is one of rapid neural and motor development, so introducing prone play during this window could, in principle, provide additional practice opportunities and build tolerance for a position many infants initially resist. Prior studies have consistently linked greater cumulative tummy-time exposure with better motor outcomes. One study of 100 caregivers found that four-month-olds with more tummy time achieved certain prone, supine, and sitting milestones earlier. A systematic review of 16 studies involving 4,237 infants across eight countries associated prone play with greater gross motor development, lower body mass index z-scores, and reduced brachycephaly, although the authors noted that most of the underlying evidence was observational and methodologically limited.

What has been missing is evidence on whether the timing of first exposure, independent of the total amount, makes a measurable difference. The new study addressed this gap directly, comparing infants who began within the first two postnatal weeks against those who began later or not at all, and tracking five developmental domains at four ages across the first year. The researchers used Kruskal-Wallis rank-sum tests, a nonparametric approach appropriate for small groups whose distributions may not meet normality assumptions, to compare score distributions across the three groups. They quantified differences with rank-based eta-squared effect sizes, estimated precision with 95 percent bootstrap confidence intervals built from 2,000 stratified resamples, and applied the Benjamini-Hochberg false-discovery-rate correction across the 20 primary domain-by-age comparisons to guard against spurious findings.

The results were largely null. Of the 20 primary comparisons, three produced unadjusted p-values below 0.05: communication at 6 months, communication at 9 months, and personal-social skills at 9 months. After correction for multiple comparisons, none remained statistically significant. The largest observed effect was for communication at 9 months, with an eta-squared of 0.275 and a 95 percent confidence interval spanning 0.100 to 0.507, followed by personal-social skills at 9 months at 0.213 and communication at 6 months at 0.155. These are nominally moderate to large effect sizes, but the confidence intervals were wide, reflecting the substantial uncertainty inherent in a sample of only 32 infants with complete five-domain data at the 3-, 6-, and 9-month assessments, and 30 infants at 12 months. The remaining comparisons produced effect estimates that were small or near zero, with confidence intervals that generally included zero.

One finding in particular caught the researchers’ attention and illustrates the hazards of overinterpreting small samples. At 9 months, the never-introduced group showed the highest mean personal-social score, at 56.9 with a standard deviation of 4.6, compared with 46.3 for the early-introduction group and 46.1 for the later-introduction group. On its face, this seems to run counter to the premise that earlier tummy time confers advantages. But the authors urge caution: the omnibus test does not establish which groups differ, the corrected p-value was not significant, and the never-introduced subgroup contained only eight infants, making its estimates exquisitely sensitive to sampling variability. The researchers also note that the study was designed to examine timing of introduction, not the independent developmental effects of tummy time itself, so comparisons involving the never-introduced group should not be read as evidence for or against the benefits of prone play.

The authors offer a plausible developmental explanation for why a transient signal might appear at 9 months and vanish elsewhere. Around this age, infants typically achieve independent sitting and increasing mobility, which transforms their opportunities for object exploration, caregiver interaction, and environmental engagement. Emerging motor skills have been linked to development in other domains, including communication and language, in prior work. These rapidly changing experiences could influence personal-social scores regardless of when tummy time began. By 12 months, accumulated motor, social, and environmental experiences may have washed out any early differences. Monthly caregiver reports of positioning, restrictive-equipment use, screen exposure, and interactive play showed broadly overlapping patterns across the tummy-time groups, suggesting that infants who started at different ages may have converged in their later experiences.

The study’s limitations are considerable and the authors are unusually candid about them. Attrition was substantial: only 30 of the 58 enrolled infants, or 51.7 percent, had complete five-domain outcomes at 12 months. Baseline comparisons between families who stayed and those who left revealed potentially meaningful imbalances, with standardized mean differences of 0.93 for maternal education, 0.68 for household income and caregiver marital status, 0.57 for paternal education, 0.49 for infant race, and 0.42 for tummy-time introduction group itself. Such differential loss to follow-up raises the risk of attrition bias, meaning the retained sample may not represent the original cohort. Both the exposure, the timing of first tummy time, and the outcome, the ASQ-3, were caregiver-reported, introducing the possibility of recall error and common-method bias. The broad later-introduction category also lumped together infants first exposed at ages ranging from two weeks to two months or older, so the actual temporal contrast between some early and later participants may have been only a few weeks, possibly too small to produce detectable differences on a broad screening instrument.

There is also the matter of what happens after introduction. The study did not standardize subsequent tummy-time practices, so infants who began later may have accumulated similar total exposure by mid-infancy, eroding any differences attributable to timing alone. Infant development is multifactorial, shaped by temperament, tolerance for prone positioning, growth, birth order, parental education, socioeconomic conditions, caregiver-infant interaction, opportunities for unrestricted movement, equipment use, screen exposure, sleep, and environmental stimulation. The sample was too small to support a stable multivariable model adjusting for these factors, meaning residual confounding is likely. The researchers calculated that a properly powered confirmatory study with three similar groups, a two-sided alpha of 0.05, 80 percent power, and a moderate effect size would require approximately 53 participants per group, or about 159 in total, rising to roughly 200 with an anticipated 20 percent attrition.

Importantly, the authors emphasize that current recommendations supporting supervised prone play should not be reconsidered based on these pilot findings. The study was never designed to evaluate whether tummy time itself benefits development, a question already addressed by a substantial prior literature, but rather whether the timing of first introduction matters. The answer, for now, is that there is no clear evidence of reproducible developmental differences by timing, and also no evidence that timing is irrelevant. The findings are best read as a map of uncertainty: preliminary patterns, wide confidence intervals, and a clear agenda for future research. Larger prospective studies with objectively documented exposure, detailed longitudinal measurement of tummy-time dose and quality, and prespecified covariate-adjusted analyses will be needed to determine whether the first fortnight of life truly represents a developmental window for prone play, or whether what matters most is simply the tummy time that follows.

Subject of Research: The relationship between the timing of tummy-time introduction in infancy and developmental outcomes during the first year of life

Article Title: Timing of tummy-time introduction and developmental outcomes during the first year of life: an exploratory pilot study

Article References: Zachry, A. H., Abdullah, F., Assfoura, R., Berke, T., Boushra, M., Ghaly, A., Khalil, M., Woods, L., & Zhao, C. (2026). Timing of tummy-time introduction and developmental outcomes during the first year of life: an exploratory pilot study. Frontiers in Pediatrics, 14, Article 1923077. https://doi.org/10.3389/fped.2026.1923077

Image Credits: AI Generated

DOI: 10.3389/fped.2026.1923077

Keywords: tummy time, infant development, ASQ-3, motor milestones, prone positioning, pilot study, pediatrics, developmental screening, attrition bias, caregiver report, American Academy of Pediatrics, early childhood

The numbers behind the syndrome remain sobering. ARDS arises from a variety of insults, including pneumonia, sepsis and trauma, and it damages both the alveolar epithelium that forms the air-blood barrier and the capillary endothelium that lines the lung’s blood vessels. That dual injury causes capillary leak, flooding the lung with protein-rich fluid, and it disrupts one of the body’s most elegant physiological tricks: hypoxic pulmonary vasoconstriction, or HPV. In a healthy lung, when a region is poorly ventilated, the tiny arteries feeding it constrict, diverting blood toward better-aerated territory. In ARDS, this reflex is impaired, so blood continues to perfuse collapsed or fluid-filled lung units. The result is intrapulmonary shunt, where blood passes through the lungs without picking up oxygen, alongside increased dead space ventilation, where air reaches regions with no blood flow to receive its carbon dioxide, and, in many patients, pulmonary hypertension.

Why does this matter so much for the patient as a whole? Because the right ventricle, the thin-walled chamber that pumps blood into the lungs, is exquisitely intolerant of pressure. The normal pulmonary circulation is a low-pressure, low-resistance, highly compliant system. In a 70-kilogram adult at rest it holds roughly 300 milliliters of blood, of which about 120 milliliters sit within the alveolar capillaries, and it can absorb large increases in cardiac output with barely a flicker of pressure rise, thanks to the recruitment of previously unperfused vessels and the distension of larger arteries. Normal pulmonary arterial systolic pressure sits between 15 and 25 millimeters of mercury. When ARDS drives vascular resistance upward, the right ventricle dilates, right atrial pressure climbs, venous return is impeded, and cardiac output falls. Right ventricular dysfunction thus becomes both a consequence of ARDS severity and an amplifier of it, disrupting ventilation-perfusion matching and perpetuating the injury.

The authors pay particular attention to the geometry of blood flow within the lung, a concept classically described by the physiologist John West. Because pulmonary arterial pressure is modest, gravity creates a hydrostatic gradient from the non-dependent, uppermost lung regions down to the dependent, lowermost ones. Where lung height exceeds arterial pressure, capillaries collapse completely and flow ceases, the so-called Zone 1; in Zone 2, capillaries partially collapse and flow is intermittent; only in Zone 3, the dependent lung, are vessels fully perfused. Positive airway pressure, the very tool used to keep ARDS patients alive, raises the pressure inside alveoli and expands these poorly perfused zones, worsening the mismatch between ventilation and perfusion. Fluid loading can mitigate the effect, but it illustrates a fundamental tension at the heart of modern ventilatory care: every breath delivered under pressure is also a hemodynamic event.

Mechanical ventilation itself reshapes the pulmonary circulation in ways that are neither linear nor intuitive. The relationship between lung volume and pulmonary vascular resistance is U-shaped. At low to moderate lung volumes, recruitment of extra-alveolar vessels actually lowers resistance, which is why an appropriately chosen level of positive end-expiratory pressure, PEEP, can recruit collapsed alveoli, improve oxygenation, reduce the hypoxic vasoconstrictive drive, and thereby unload the right ventricle. Push lung volume higher, however, and the intra-alveolar vessels are compressed, resistance climbs, and right ventricular afterload rises with it. Excessive tidal volumes also risk ventilator-induced lung injury through direct mechanical stress on alveoli, and the authors highlight a second, less familiar mechanism: the large cyclic swings in right ventricular stroke volume and pulmonary blood flow produced by each breath may themselves induce overperfusion-related vascular stress.

The clinical footprint of this vascular failure is well characterized. Acute cor pulmonale, defined echocardiographically by right ventricular dilation and paradoxical motion of the interventricular septum, occurs in a substantial share of patients with moderate-to-severe ARDS. Known risk factors include pneumonia as the underlying cause, a driving pressure of 18 millimeters of mercury or higher, a ratio of arterial oxygen to inspired oxygen fraction below 150, and an arterial carbon dioxide tension of 48 millimeters of mercury or more. Elevated pulmonary vascular resistance is independently associated with mortality. As resistance rises and the right ventricle dilates, the shared septum bulges into the left ventricle, limiting its filling through ventricular interdependence, and cardiac output drops further. The authors also describe a striking bedside phenomenon first termed the low tide: during each insufflation, right ventricular stroke volume falls, producing measurable swings in pulmonary arterial and systemic pulse pressure. In ARDS patients, systemic pulse pressure variation is associated with worse outcomes, though the authors caution that such dynamic indices are not specific enough on their own, and that assessing the cardiac output response to a passive leg raise remains the more reliable test of fluid responsiveness.

From this physiology flows a treatment philosophy that departs from the aggressive open-lung strategies of recent years. The optimal ventilatory approach, the authors contend, is the one that minimizes blood gas abnormalities while preserving the pulmonary circulation, promoting recruitment rather than overdistension. Because lung injury in ARDS is profoundly heterogeneous, global compliance measurements can be misleading, so the authors advocate a combination of limited tidal volumes and plateau pressures, minimization of driving pressure, careful titration of PEEP to oxygenation, and avoidance of hypercapnia. They point to emerging bedside tools, including electrical impedance tomography, which maps regional ventilation in real time, and the recruitment-to-inflation ratio, as promising ways to explore at the bedside how a given ventilatory strategy affects the pulmonary circulation and the right ventricle. Combining echocardiography with respiratory mechanics monitoring, they suggest, can verify the delicate balance between protecting the lung and protecting the heart.

For the most severely affected patients, the therapeutic ladder extends further. Prone positioning, turning the patient face-down, improves lung mechanics and aeration, reverses dependent alveolar collapse and small-airway air trapping, and, crucially, preserves pulmonary perfusion in the dorsal lung regions, reducing vascular resistance and improving hemodynamics. When prone positioning fails to achieve adequate gas exchange, veno-venous extracorporeal membrane oxygenation can take over part of the gas exchange burden, and it does something remarkable to the circulation as well: by improving oxygenation and reducing the pressure the right ventricle must generate, it lowers pulmonary artery pressure, unloads the right ventricle and increases cardiac output. These interventions, the authors argue, succeed in part precisely because they rescue the pulmonary circulation, not just the lung parenchyma.

The broader message is a call for intellectual realignment in the intensive care unit. Sixty years after Ashbaugh’s landmark description of the syndrome, the authors write that understanding has shifted from a purely respiratory disorder to a dual pathology involving both lung tissue and lung vasculature. An integrated strategy that optimizes oxygenation and ventilation through lung recruitment while minimizing hemodynamic compromise may be more appropriate than traditional open-lung approaches, which risk trading acceptable blood gases for a failing right heart. There are honest gaps in the framework, and the authors acknowledge them: no threshold level of PEEP guarantees hemodynamic safety, because the impact of raising PEEP depends on whether the lung recruits or simply overdistends, and estimates of pulmonary vascular resistance can be obscured by Zone 2 conditions within the injured lung. Even so, the direction of travel is clear. By preserving pulmonary vascular function, clinicians may be able to optimize gas exchange and support cardiac function simultaneously, treating ARDS not as a lung disease with circulatory side effects, but as what it has been all along: a disease of the heart-lung unit.

For a condition that has resisted six decades of therapeutic advances, the reframing carries real weight. It suggests that some of the mortality attributed to refractory hypoxemia may in fact be hemodynamic failure in disguise, visible only to the clinician who thinks to look at the right ventricle and the vessels feeding it. It also offers a unifying explanation for why protective ventilation, prone positioning and extracorporeal support all improve survival: each, in its own way, protects the pulmonary circulation. As monitoring technology brings echocardiography, impedance tomography and respiratory mechanics together at the bedside, the vision of a truly heart-lung-centered approach to ARDS is moving from physiology textbook to daily practice, and that shift may prove to be one of the most consequential ideas in critical care this decade.

Subject of Research: Pulmonary vascular dysfunction and right ventricular failure in acute respiratory distress syndrome

Article Title: The pulmonary circulation in ARDS: from pathophysiology to clinical applications

Article References: Vieillard-Baron, A., Chew, M., & Pinsky, M. R. (2026). The pulmonary circulation in ARDS: from pathophysiology to clinical applications. Intensive Care Medicine. https://doi.org/10.1007/s00134-026-08597-x

Image Credits: AI Generated

DOI: 10.1007/s00134-026-08597-x

Keywords: ARDS, pulmonary circulation, right ventricular dysfunction, pulmonary hypertension, mechanical ventilation, PEEP, acute cor pulmonale, hypoxic pulmonary vasoconstriction, prone positioning, ECMO, ventilator-induced lung injury, hemodynamics

The research team, led by Annika Meyer of University Hospital Cologne together with colleagues from several German institutions, conducted the review in accordance with PRISMA 2020 guidelines and registered the protocol prospectively before data collection began. In January and February 2026, the investigators searched PubMed, Web of Science, Dimensions AI, The Lens, and the Cochrane Library, supplemented by screening of Google Scholar records and, notably, by artificial intelligence-assisted literature discovery tools including ChatGPT 5.2, OpenEvidence, and SciSpace, which were used in a supplementary role to catch studies that conventional database queries might have missed. The search yielded 778 records, from which ten studies encompassing 177 neurocritical care patients in Europe and China ultimately met the inclusion criteria. Eight of those studies, covering 120 patients, provided extractable data for the meta-analysis of the primary outcome: the change in intracranial pressure from a supine baseline to the prone position.

The pooled results showed a statistically significant but modest rise in intracranial pressure of 5.06 millimeters of mercury when patients were turned prone, with a 95 percent confidence interval spanning 2.05 to 8.06 millimeters of mercury. Between-study heterogeneity was substantial, with an I-squared statistic of 76.7 percent, reflecting the wide variety of protocols, patient populations, and positioning techniques across the included studies. In descriptive terms, pooled mean intracranial pressure increased from 11.10 millimeters of mercury at baseline to 16.13 millimeters of mercury during proning. Crucially, both values remained below the treatment thresholds commonly used to define intracranial hypertension, which typically begin around 20 to 22 millimeters of mercury. The increase, in other words, was real but generally did not push patients into the danger zone.

Perhaps the most clinically important finding concerned what happened after patients were turned back. In five studies with 45 patients, the pooled change in intracranial pressure between the supine baseline and the period after returning to supine was minus 0.41 millimeters of mercury, with a confidence interval of minus 2.34 to 1.51, meaning there was no meaningful difference from pre-proning values. The pressure elevation during proning was therefore transient and fully reversible, a position-dependent effect rather than a sustained deterioration of intracranial dynamics. Cerebral perfusion pressure, the gradient that actually drives blood flow to brain tissue, showed no significant change either during proning or afterward, with mean differences close to zero and wide confidence intervals. Only one included study reported vasopressor adjustments, and no changes in vasopressor requirements were observed during the prone phase.

Against this modest hemodynamic cost, the respiratory benefits were consistent and striking. Every one of the ten studies that reported systemic oxygenation parameters, whether the partial pressure of arterial oxygen alone or the PaO2-to-FiO2 ratio, documented improvement during prone positioning. Four studies went further and measured invasive brain tissue oxygenation directly, using parenchymal sensors, and found that brain tissue oxygen levels also rose while patients were prone. This detail carries particular weight because, in three of the four studies, baseline brain tissue oxygenation values fell within ranges previously associated with cerebral ischemia and unfavorable neurological outcomes. In one study, brain tissue oxygenation improved during proning even as cerebral perfusion pressure declined slightly, suggesting that better oxygenation of arterial blood can translate into better oxygen delivery to tissue even when perfusion pressure shifts modestly.

The physiological mechanism behind the transient pressure rise is well understood from decades of neurosurgical anesthesia practice. Prone positioning increases intrathoracic and intraabdominal pressures, which can impede cerebral venous outflow, and suboptimal head and neck alignment can compromise jugular venous drainage. Because the skull is a rigid compartment governed by the Monro-Kellie doctrine, any increase in venous blood volume must be offset by displacement of cerebrospinal fluid or arterial blood, and patients with limited intracranial compliance have less reserve to absorb the change. Consistent with this framework, several included studies found that tolerance of proning was usually apparent within the first hour and was associated with lower baseline intracranial pressure. One study observed larger pressure increases in patients without external ventricular drainage, underscoring the role of cerebrospinal fluid diversion in preserving intracranial reserve.

The clinical relevance of a five-millimeter-of-mercury rise is therefore highly patient dependent. In individuals with preserved compensatory reserve, the transient elevation can be buffered by normal autoregulatory displacement of fluid compartments. In patients already hovering near the threshold of intracranial hypertension, however, the same increase may exhaust the remaining reserve and trigger an exponential rise in pressure. This helps explain why, across six studies that reported it, roughly 8.89 percent of patients had prone positioning prematurely discontinued because of intracranial pressure elevation, with a confidence interval of 4.21 to 17.78 percent. The authors suggest a pragmatic interpretation: rather than treating proning as a binary yes-or-no decision, clinicians should implement it as a monitored therapeutic trial with an explicit early reassessment point, typically within the first hour, when vulnerability is most likely to declare itself.

The evidence base behind these conclusions comes with important caveats that the authors address candidly. Only two of the ten studies were randomized trials, and one of those was judged to have a high risk of bias due to problems with the randomization process and missing outcome data, while the other raised some concerns. The eight nonrandomized studies carried an overall moderate risk of bias, driven primarily by serious confounding and selective reporting. Using the GRADE framework, the overall certainty of evidence was rated very low. Notably, patients with intracranial pressure monitoring have been excluded from roughly 75 percent of prior trials evaluating prone positioning for acute respiratory distress syndrome, which is precisely why this population has remained so poorly characterized. Additional limitations include inconsistent control of arterial carbon dioxide levels, a major determinant of cerebral blood flow, and the fact that brain tissue oxygenation reflects only regional rather than global oxygen delivery.

The heterogeneity across studies also extended to technique, and the authors argue that positioning details are far from trivial technicalities. Whether patients were placed fully prone or semi-prone, whether the head was elevated or horizontal, and whether the head was kept neutral or rotated are likely to be major determinants of intracranial tolerance. Turning maneuvers themselves can provoke coughing, ventilator desynchrony, and sympathetic activation, all of which acutely raise intracranial pressure, while concomitant spinal injuries, which are relatively common in traumatic brain injury, can complicate mobilization. Excessive sedation stabilizes physiology but delays neurological assessment, a tradeoff that cannot be eliminated but can be managed through protocolized practice.

The bottom line for clinicians is a cautious green light. The findings support considering prone positioning in selected neurocritical care patients with moderate-to-severe hypoxemic respiratory failure when invasive intracranial pressure monitoring is in place and timely de-escalation pathways are available, in line with European Society of Intensive Care Medicine consensus recommendations that already endorse proning when intracranial pressure is not elevated. Because hypoxemia is a major driver of secondary brain injury, and pulmonary complications affect an estimated 5 to 30 percent of acute brain injury patients while worsening outcomes and prolonging intensive care stays, the stakes of leaving respiratory failure untreated are considerable. The authors emphasize that current evidence supports a cautious approach but not definitive thresholds or protocols, and they call for larger prospective studies using standardized proning protocols, time-resolved intracranial pressure data, stratification by baseline intracranial reserve, and patient-centered neurological outcomes. Until such trials arrive, the message from this analysis is that the feared catastrophe of proning the injured brain is, in most monitored patients, a manageable and reversible bump rather than a cliff edge.

Subject of Research: Effects of prone positioning on intracranial pressure and oxygenation in neurocritical care patients with invasive intracranial pressure monitoring

Article Title: Prone Positioning in Neurocritical Care Patients with Invasive Intracranial Pressure Monitoring: A Systematic Review and Meta-analysis

Article References: Meyer, A., Overbeek, R., Mühlhausen, L., Küchler, J., Ditz, C., Foit, A., Hof, M., Goldbrunner, R., & Steinbicker, A. U. (2026). Prone Positioning in Neurocritical Care Patients with Invasive Intracranial Pressure Monitoring: A Systematic Review and Meta-analysis. Neurocritical Care. https://doi.org/10.1007/s12028-026-02667-0

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02667-0

Keywords: prone positioning, intracranial pressure, neurocritical care, acute brain injury, ARDS, cerebral perfusion pressure, brain tissue oxygenation, systematic review, meta-analysis, traumatic brain injury, subarachnoid hemorrhage, intensive care medicine

The review’s central reframing is subtle but consequential. Historically, adjuvant therapies were held back as rescue strategies, deployed only when refractory hypoxemia left clinicians with no other options. Current guidelines, by contrast, recommend applying them earlier in the disease course, reflecting the importance of minimizing stress and strain on the injured lung and potentially modulating the immune dysregulation that drives the syndrome. The authors organize commonly used adjuvants not by fashion or habit, but by the relative certainty of their utility and the frequency of their use—a taxonomy that reveals an uncomfortable truth: how often a therapy is used does not always match how well the evidence supports it.

At the top of the evidence hierarchy sits prone positioning, one of the most effective non-pharmacologic strategies for reducing mortality in moderate-to-severe ARDS. Its benefits extend well beyond improved oxygenation. Turning a patient face-down redistributes transpulmonary pressures more homogeneously across the lung, reduces overdistension of dorsal regions, recruits collapsed dependent lung tissue, and mitigates ventilator-induced lung injury. The PROSEVA trial demonstrated a substantial mortality reduction when prone positioning was applied early and for prolonged sessions in severe ARDS, and subsequent meta-analyses confirmed the benefit was greatest when it was combined with low-tidal-volume ventilation and sustained for more than sixteen hours per session. Despite this strong evidence and guideline endorsement, real-world adoption remains inconsistent, hampered by logistical demands and variability in clinician familiarity—a gap the authors describe as both common and serious.

Continuous neuromuscular blockade occupies a more contested middle ground. The physiological rationale is compelling: paralytic agents halt patient–ventilator dyssynchrony, eliminate excessively forceful spontaneous breathing efforts that can themselves injure the lung, control transpulmonary pressures, and reduce oxygen consumption. The ACURASYS trial showed improved survival and less barotrauma with a 48-hour course of early neuromuscular blockade in patients with moderate-to-severe but persistent ARDS. But the later ROSE trial, which applied the drugs slightly earlier in the disease course, found no mortality benefit. The discrepancy may reflect evolving practice—ROSE was conducted amid lighter sedation and higher PEEP, which may have blunted the incremental value of paralysis—or the fact that ACURASYS enrolled patients slightly later, enriching the study population for persistent, harder-to-treat disease. Current guidance favors short-course, targeted use, balanced against the risks of diaphragmatic inactivity and ICU-acquired weakness.

Conservative fluid management tells a different kind of story: modest evidence, near-universal adoption. Pulmonary edema worsens hypoxemia, decreases lung compliance, and amplifies ventilator-induced injury, so draining excess fluid with diuretics—or occasionally renal replacement therapy—directly supports the goals of lung-protective ventilation. The FACTT trial found that a conservative fluid strategy improved oxygenation, shortened the duration of mechanical ventilation, and reduced ICU length of stay, though it produced no mortality benefit. Even without a survival signal, the approach has become standard supportive care, fitting neatly into a broader philosophy of de-resuscitation: meticulous fluid stewardship for critically ill patients who have already received aggressive resuscitation, regardless of whether they carry an ARDS diagnosis.

Corticosteroids, meanwhile, have ridden decades of enthusiasm and disappointment. By attenuating the inflammatory cascade underlying ARDS, steroids promise reduced alveolar inflammation and less fibroproliferation. Recent trials and meta-analyses suggest early corticosteroids may shorten mechanical ventilation and ICU stays, particularly when initiated early in moderate-to-severe disease, and the COVID-19 pandemic cemented dexamethasone as standard care for severe hypoxemic viral pneumonia. Yet uncertainty persists over optimal dosing, duration, and applicability across etiologies. In late-phase ARDS, the evidence is mixed at best: an early trial of prolonged methylprednisolone in unresolving disease was followed by a larger study that failed to replicate a mortality benefit and raised a late mortality signal when treatment began more than fourteen days after ARDS onset. The authors conclude that steroids are best considered a phenotype-dependent therapy rather than a universally effective one, with trial heterogeneity likely reflecting biological differences among patients rather than absent efficacy.

Then there are the therapies that persist despite thin evidence. Inhaled pulmonary vasodilators—nitric oxide and epoprostenol—offer an elegant physiological fix for severe hypoxemia, selectively directing blood flow toward better-ventilated alveoli and reducing pulmonary vascular resistance. Studies consistently show transient oxygenation improvements, but none has demonstrated a mortality benefit, and harms such as renal dysfunction are documented. Guidelines do not recommend routine use. Nevertheless, inhaled vasodilators remain widely employed as short-term bridges to prone positioning, transfer, or escalation to extracorporeal support, and they may ease right ventricular afterload in acute cor pulmonale, though that indication has never been tested in randomized trials. Their persistence, the authors note, embodies the recurring tension between immediate physiological rescue and outcome-based evidence.

The deeper message of the review is that the right question is no longer whether an adjuvant works, but which therapy should be applied, in which patient, at what stage of disease, and to achieve which physiological objective. Timing matters as much as selection: prone positioning early and for long sessions in severe disease, neuromuscular blockade selectively when dyssynchrony and injurious breathing efforts dominate, fluids tightened once resuscitation is complete, steroids matched to inflammatory phenotype and etiology. The authors propose a framework mapping each adjuvant onto the evolving phases of ARDS, treating the syndrome as a moving target rather than a static diagnosis. Static classification at the bedside, they suggest, may ultimately matter less than dynamic reassessment throughout the illness.

Looking forward, the future of adjuvant therapy may be defined less by discovering new drugs than by deploying existing ones better. Advances in phenotyping—biological, physiological, and imaging-based—could identify which patients benefit from which interventions. The hyperinflammatory and hypoinflammatory subphenotypes described by Calfee and colleagues have already shown differential responses to several therapies, suggesting treatment effect varies with host biology rather than the syndrome label alone. Physiological phenotyping—respiratory mechanics, recruitability, respiratory drive, right ventricular function—may sharpen selection further. Equally important, the authors argue, is a willingness to de-adopt therapies lacking a strong evidence base. Adjuvants, they conclude, should not be regarded as rescue therapies of last resort but as targeted tools applied thoughtfully within a broader lung-protective strategy. The goal is deceptively simple to state and hard to achieve: the right adjuvant, for the right patient, at the right time.

Subject of Research: Adjuvant therapies for acute respiratory distress syndrome across the course of the disease

Article Title: Beyond the ventilator: deploying adjuvant therapies across the course of ARDS

Article References: Munshi, L., Rubenfeld, G., & Wunsch, H. (2026). Beyond the ventilator: deploying adjuvant therapies across the course of ARDS. Intensive Care Medicine, 52(9), 2026-2030. https://doi.org/10.1007/s00134-026-08594-0

Image Credits: AI Generated

DOI: 10.1007/s00134-026-08594-0

Keywords: ARDS, mechanical ventilation, prone positioning, neuromuscular blockade, corticosteroids, conservative fluid management, inhaled pulmonary vasodilators, lung-protective ventilation, phenotyping, critical care, ventilator-induced lung injury, intensive care medicine